BIO, PhRMA, and AdvaMed Submit Comments in response to Canada's WTO Notification
<p>
On behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Advanced Medical Technology Association (AdvaMed), we hereby provide formal written comments in response to Canada's WTO notifcation</p>
Dear Sir or Madam:
On behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Advanced Medical Technology Association (AdvaMed), we hereby provide formal written comments in response to Canada's WTO notifcation, dated August 26, 2014, related to the proposed passage of Bill C-17, An Act to Amend the Food and Drug Act(hereinafter referred to as the "Bill"). While the Bill makes a number of necessary revisions to the Food and Drug Act, certain amendments proposed and passed by Canada's House of Commons in June conflict with Canada's international obligations under the WTO Technical Barriers to Trade (TBT) Agreement and the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.
